Amended Claims:

1 (Currently Amended). A compound of formula (I),



(I),

or a pharmaceutically suitable salt or prodrug thereof, wherein

A is a member selected from the group consisting of



B and C are each independently a member selected from the group consisting of aryl, and heterocycle;

R_1 is a member a member selected from the group consisting of alkyl, alkoxy, alkylSO$_2$, trifluoroalkylSO$_2$, trifluoroalkylNH-, alkylSO$_2$NH-, carboxy, cyano, HONHcarbonyl, R_aONHcarbonyl, nitro, R_aOC(O)-, HO_3S-, H_2NO_2S-, R_aNHO_2S-, $(HO)_2(O)P$-, $(HO)_2(O)PCH_2$-, $(HO)_2(O)PCHF$-, $(HO)_2(O)PCF_2$- and heterocycle, wherein said heterocycle is a member selected from the group consisting of:



R_2, R_3, R_4, R_5, R_6 and R_7 are each independently absent or are independently a member selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, aryl, arylcarbonyl, arylalkyl, carboxy, carboxyalkyl, cyano, cycloalkyl, cycloalkylalkyl, halo, haloalkyl, heterocycle, heterocyclecarbonyl, heterocyclealkyl, hydroxy, hydroxyalkyl, nitro, trihaloalkyl, R_aR_bN, $R_aR_bN$alkyl, $R_aR_bN$carbonyl, , $R_aR_bN$carbonylalkyl, $R_aR_bNN$sulfonyl, $R_aR_bNN$sulfonylalkyl, wherein R_a and R_b are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxycarbonyl, alkylcarbonyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, and heterocyclealkyl;

L is –G-X_1-J-X_2-K- ~~**or a bond**~~;

G, J and K are independently a member selected from the group consisting of a bond, alkyl, alkenyl, aryl and cycloalkyl, wherein said alkyl, alkenyl, aryl and cycloalkyl may be optionally substituted with a group consisting of alkoxy, alkyl, halogen, hydroxy, hydroxyalkyl, carboxy and R_dR_eN-, wherein R_d and R_e are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxycarbonyl, alkylcarbonyl and arylalkyl;

X_1 and X_2 are each independently a member selected from the group consisting of a bond, –O-, -N(R_c)-, -N(R_c)C(O)-, -C(O)N(R_c)-, -N(R_c)S(O)$_2$-, -S(O)$_2$N(R_c)-, and -C(O), wherein R_c is a member selected from the group consisting of hydrogen, alkyl and arylalkyl**, provided that both X_1 and X_2 are not a bond**; and

provided that if J is absent, then at least one of X_1 and X_2 must be absent.

2 (Currently Amended). A compound of formula (II),



~~(II),~~



(II),

or a pharmaceutically suitable salt or prodrug thereof, wherein

R_1 is a member selected from the group consisting of alkyl, alkoxy, $alkylSO_2$, $trifluoroalkylSO_2$, $trifluoroalkylNH$-, $alkylSO_2NH$-, carboxy, cyano, HONHcarbonyl, $R_aONHcarbonyl$, nitro, $R_aOC(O)$-, HO_3S-, H_2NO_2S-, R_aNHO_2S-, $(HO)_2(O)P$-, $(HO)_2(O)PCH_2$-, $(HO)_2(O)PCHF$-, $(HO)_2(O)PCF_2$- and heterocycle, wherein said heterocycle is a member selected from the group consisting of:



~~R_2~~, R_3, R_4, R_5, R_6 and R_7 are each independently absent or are independently a member selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, aryl, arylcarbonyl, arylalkyl, carboxy, carboxyalkyl, cyano, cycloalkyl, cycloalkylalkyl, halo, haloalkyl, heterocycle, heterocyclecarbonyl, heterocyclealkyl, hydroxy, hydroxyalkyl, nitro, trihaloalkyl, R_aR_bN, $R_aR_bN$alkyl, $R_aR_bN$carbonyl, , $R_aR_bN$carbonylalkyl, $R_aR_bNN$sulfonyl, $R_aR_bNN$sulfonylalkyl, wherein R_a and R_b are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxycarbonyl, alkylcarbonyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, and heterocyclealkyl;

L is $-G-X_1-J-X_2-K-$ ~~or a bond~~;

G, J and K are independently a member selected from the group consisting of a bond, alkyl, alkenyl, aryl and cycloalkyl, wherein said alkyl, alkenyl, aryl and cycloalkyl may be optionally substituted with a group consisting of alkoxy, alkyl, halogen, hydroxy, hydroxyalkyl, carboxy and R_dR_eN-, wherein R_d and R_e are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxycarbonyl, alkylcarbonyl and arylalkyl;

X_1 and X_2 are each independently a member selected from the group consisting of a bond, –O-, $-N(R_c)-$, $-N(R_c)C(O)-$, $-C(O)N(R_c)-$, $-N(R_c)S(O)_2-$, $-S(O)_2N(R_c)-$, and -C(O)-, wherein R_c is a member selected from the group consisting of hydrogen, alkyl and arylalkyl**, provided that both X_1 and X_2 are not a bond**; and

provided that if J is absent, then at least one of X_1 and X_2 must be absent.

3 (Original). The compound according to claim 2, wherein

G is a member selected from the group consisting of alkyl, alkenyl and cycloalkyl.

4 (Original). The compound according to claim 2, wherein

G is a member selected from the group consisting of alkyl, alkenyl and cycloalkyl; and

X_1, J and K are a bond.

5 (Original). The compound according to claim 2, wherein
G is a member selected from the group consisting of alkyl, alkenyl and cycloalkyl; and
X_1, J and K are a bond; and
R_1 is CO_2H.

6 (Original). The compound according to claim 5, a member selected from the group consisting of

5-(3-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-(3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)butyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-((2-(3-hydroxy-2-(methoxycarbonyl)phenoxy)ethyl)amino)phenyl)isoxazole-3-carboxylic acid;

5-(3-(3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)propyl)phenyl)isoxazole-3-carboxylic acid;

5-(2-fluoro-5-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-((1E)-3-(3-hydroxy-2-nitrophenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-((1S,2S)-2-((3-hydroxy-2-(methoxycarbonyl)phenoxy)methyl)cyclopropyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-(3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)butyl)-4-methoxyphenyl)isoxazole-3-carboxylic acid;

5-(4-fluoro-3-(3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)butyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-(3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)pentyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-((1E)-3-(3-hydroxy-2-propionylphenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-((1E)-4-hydroxy-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)but-1-enyl)phenyl)isoxazole-3-carboxylic acid;

5-(1-(2-(3-hydroxy-2-(methoxycarbonyl)phenoxy)ethyl)-1H-indol-6-yl)isoxazole-3-carboxylic acid;

5-(3-((1E)-3-(2-(acetylamino)-3-hydroxyphenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-((1E)-3-(2-((benzylamino)carbonyl)-3-hydroxyphenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)-4-nitrophenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;

4-amino-5-(3-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;

5-(3-((1*E*)-3-((3',5-dihydroxy-4-(methoxycarbonyl)-1,1'-biphenyl-3-yl)oxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid; and

5-(3-{(1*E*)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl}phenyl)-4-(hydroxymethyl)isoxazole-3-carboxylic acid.

7 (Original). The compound according to claim 2, wherein
X_1 is a member selected from the group consisting of –NH- and –NHC(O)-.

8 (Original). The compound according to claim 2, wherein
X_1 is a member selected from the group consisting of –NH- and –NHC(O)-; and
G and K are a bond.

9 (Original). The compound according to claim 2, wherein
X_1 is a member selected from the group consisting of –NH- and –NHC(O)-;
G and K are a bond; and
R_1 is CO_2H.

10 (Original). The compound according to claim 9, a member selected from the group consisting of

5-(3-(((1-acetylpiperidin-4-yl)carbonyl)amino)phenyl)isoxazole-3-carboxylic acid;

5-(3-((2-(3-hydroxy-2-((methylamino)carbonyl)phenoxy)ethyl)amino)phenyl)isoxazole-3-carboxylic acid; and

5-(3-((1E)-3-(3-hydroxy-2-((methylamino)carbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid.

11 (Canceled). The compound according to claim 2 wherein
L is a bond.

12 (Original). The compound according to claim 2 wherein

L is a bond; and

R_1 is CO_2H.

13 (Original). The compound according to claim 12 that is
5-{3'-(3-(carboxy)isoxazol-5-yl)-1,1'-biphenyl-3-yl}isoxazole-3-carboxylic acid.

14 (Original). A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically suitable carrier.

15 (Canceled).

16 (Canceled).

17 (Canceled).

18 (Canceled).

19 (Canceled).